Dental News - COLTENE to acquire dental companies SciCan and MICRO-MEGA

Search Dental Tribune

COLTENE to acquire dental companies SciCan and MICRO-MEGA

COLTENE’s acquisition of dental companies SciCan and MICRO-MEGA is intended to boost sales in the core areas of infection control and endodontics. (Photograph: Saklakova/Shutterstock)

Wed. 27. June 2018

save

ALTSTÄTTEN, Switzerland: COLTENE, an internationally leading developer and manufacturer of dental equipment and materials, has signed an agreement to acquire SciCan and MICRO-MEGA, which both hold strong positions in their respective markets. They are independent companies controlled by the same owners and generated total sales revenues of about CHF97 million (€84 million) in 2017 with a combined workforce of about 410 employees. With the planned integration of the two dental specialists, COLTENE anticipates that its sales will increase significantly.

The transaction is aimed at strengthening COLTENE’s market reach and product range, creating synergy potential, and enhancing its offering in infection control and endodontics. With its combined resources, the enlarged group will be in an even better position to address compliance and regulation standards. Moreover, economies of scale will support effective, high-performing sales and marketing activities worldwide. Ultimately, the merger of the three corporate entities is hoped to create attractive growth opportunities in the highly competitive dental market.

SciCan, headquartered in Toronto in Canada, offers cleaning and sterilisation equipment and hygiene protection products. It has about 230 employees, is active worldwide and claims a market leading position in North America. MICRO-MEGA, based in Besançon in France, employs approximately 180 people and is focused primarily on endodontic instruments. Most of its sales are generated in Europe and North America. COLTENE intends to retain all manufacturing and product expertise of SciCan and MICRO-MEGA at their current sites of operation. Likewise, SciCan’s and MICRO-MEGA’s products and brands with their excellent market reputation will be retained under the overarching COLTENE brand. The enlarged COLTENE group will have a combined workforce of approximately 1,300.

Sales of SciCan and MICRO-MEGA in the endodontics business area totalled around CHF23 million (about €20 million) in 2017 and approximately CHF74 million (about €64 million) in the infection control area. Around CHF23 million was generated in the Europe, the Middle East and Africa region, around CHF63 million (about €55 million) in North America and CHF11 million (about €10 million) in Asia.

After completion of the adjustments stipulated in the purchase agreement, the purchase price at closing is expected to amount to approximately CHF195 million (about €160 million). COLTENE intends to finance around three-quarters of this sum with equity and one-quarter with borrowed capital.

The COLTENE Group’s management will be expanded with Stefan Helsing to ensure adept representation of the new locations and product groups. Currently, Helsing is CEO of the Sanavis Group, to which SciCan and MICRO-MEGA belong. The COLTENE board of directors also intends proposing the election of Dr Allison Zwingenberger, Arthur Zwingenberger’s daughter, at an extraordinary general meeting of COLTENE, which has been tentatively scheduled for the end of the third quarter of this year. She is an associate professor in the Department of Surgical and Radiological Sciences in the School of Veterinary Medicine at the University of California, Davis, in the US, and has extensive knowledge of international medical markets.

Tags:
To post a reply please login or register
advertisement
advertisement